More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$468036051
EPS
0.5
P/E ratio
8.8
Price to sales
1.89
Dividend yield
--
Beta
2.565421
Previous close
$5.42
Today's open
$5.37
Day's range
$5.21 - $5.46
52 week range
$3.95 - $6.50
show more
CEO
Robert S. Wiesenthal
Employees
601
Headquarters
New York, NY
Exchange
NASDAQ Capital Market
Shares outstanding
89319857
Issue type
Common Stock
Industrials
Transportation
Strata Critical Medical, Inc. (SRTA) Presents at 2026 UBS Global Healthcare Conference Transcript
Strata Critical Medical, Inc. (SRTA) Presents at 2026 UBS Global Healthcare Conference Transcript
Seeking Alpha • Nov 10, 2026

Strata Critical Medical Q3 Earnings Call Highlights
Strata Critical Medical NASDAQ: SRTA reported fiscal third-quarter 2026 revenue growth of 50.3% from a year earlier, alongside higher adjusted EBITDA, improved logistics margins and record free cash flow, as the company expanded its integrated transplant-services platform.
MarketBeat • Nov 3, 2026

Strata Critical Medical, Inc. (SRTA) Q3 2026 Earnings Call Transcript
Strata Critical Medical, Inc. (SRTA) Q3 2026 Earnings Call Transcript
Seeking Alpha • Nov 3, 2026

Strata Critical Medical Announces Third Quarter 2026 Results
Revenue increased 50.3% year-over-year to $74.1 million in Q3 2026 Clinical revenue increased 20.3% sequentially in Q3 2026 vs Q2 2026 Q3 2026 net loss from continuing operations of $(7.6) million or (10.3)% of revenue Adjusted EBITDA (1) of $9.6 million in Q3 2026; Adjusted EBITDA margin of 13.0% Cash flow from operating activities was $9.5 million in Q3 2026; Free Cash Flow (1) was $8.6 million in Q3 2026 Announced $20 million share repurchase authorization; will be deployed along with continued M&A strategy execution NEW YORK, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (Nasdaq: SRTA, "Strata" or the "Company"), today announced financial results for the third quarter ended September 30, 2026. Financial results in this release, including all comparisons to prior year periods, reflect continuing operations only.
GlobeNewsWire • Nov 3, 2026

Strata Critical Medical to Present at the UBS Global Healthcare Conference
NEW YORK, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (Nasdaq: SRTA, “Strata” or the “Company”), today announced that management will present at the UBS Global Healthcare Conference on Tuesday, November 10th, 2026 at 12:30 pm ET. A webcast of the event will be available at the link here.
GlobeNewsWire • Nov 3, 2026

Strata Critical Medical Schedules Third Quarter 2026 Earnings Conference Call
NEW YORK, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical. (Nasdaq: SRTA, “Strata” or the “Company”), will release financial results for the third quarter ended September 30, 2026 on Tuesday, November 3, 2026 before the market opens. The company will hold a conference call on the same day at 8:00 am Eastern Time to discuss the results. The call will be hosted by Melissa Tomkiel, Strata's Co-Chief Executive Officer and General Counsel, and Will Heyburn, Strata's Co-Chief Executive Officer and Chief Financial Officer, and will include a question-and-answer session for call participants.
GlobeNewsWire • Oct 23, 2026

Strata Critical to Present at the 2026 Jefferies Healthcare Services and Technology Conference
NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (Nasdaq: SRTA, “Strata” or the “Company”), today announced that management will present at the 2026 Jefferies Healthcare Services and Technology Conference on Monday, September 14, 2026, at 2:15 pm ET. A webcast of the event will be available at the link here. A replay will be available shortly after the conclusion of the presentation on the investor relations section of the Company's website at https://ir.stratacritical.com/.
GlobeNewsWire • Sep 8, 2026

Does Strata Critical Medical, Inc. (SRTA) Have the Potential to Rally 47.28% as Wall Street Analysts Expect?
The mean of analysts' price targets for Strata Critical Medical, Inc. (SRTA) points to a 47.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks Investment Research • Aug 24, 2026

Strata Critical Medical, Inc. (SRTA) Upgraded to Buy: What Does It Mean for the Stock?
Strata Critical Medical, Inc. (SRTA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks Investment Research • Aug 24, 2026

Can Strata Critical Medical, Inc. (SRTA) Run Higher on Rising Earnings Estimates?
Strata Critical Medical, Inc. (SRTA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Zacks Investment Research • Aug 6, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Strata Critical Medical Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.